Christoph Kampmann1, Amandine Perrin2, Michael Beck3. 1. Section Head for Congenital Heart Defects, Center for Pediatric and Adolescent Medicine, University Medical Center, University of Mainz, Langenbeckstr. 1, Mainz, DE-55101, Germany. kampmann@mail.uni-mainz.de. 2. Statistical Programmer, Rare Diseases Business Unit, Global Outcomes Research, Shire, Zug, Switzerland. 3. Professor Emeritus, Department of Pediatrics, University Medical Center, University of Mainz, Mainz, Germany.
Following the publication of our article “Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment” by Kampmann et al. [1] we have become aware that the dose of agalsidase alfa was not reported.Eligible patients had a Fabry disease diagnosis confirmed by enzyme assay (males) and/or DNA analysis (males and females), were aged ≥14 years at treatment start, and had received agalsidase alfa (Replagal®; Shire, Lexington, Massachusetts, USA) ERT at a dose of 0.2 mg/kg body weight every other week for approximately 10 years.